EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients

• Status: Completed
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety of the drug EPO906 that could shrink tumors when used with radiation therapy in cancer patients.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University; Thomas Jefferson University
• Collaborator: Novartis Pharmaceuticals
• Treatments: Epothilone B; Epothilones

Criteria

Inclusion Criteria:

• Requires a minimum of 3 weeks of radiation therapy

• Solid tumors with advanced or recurrent disease for which there is no standard therapy or tumors have failed standard therapy

• World Health Organization (WHO) performance status equal to or less than 2

• Life expectancy equal to or greater than 3 months

Exclusion Criteria:

• Any peripheral neuropathy

• Unresolved diarrhea greater than grade 1

• Patients who received any other investigational compound within the past 28 days

• Severe cardiac insufficiency

• Patients on Coumadin